Astaxanthin Ameliorates Skeletal Muscle Atrophy in Mice With Cancer Cachexia.
Nutr Cancer
; 76(6): 529-542, 2024.
Article
em En
| MEDLINE
| ID: mdl-38567899
ABSTRACT
Astaxanthin (AST) is a natural marine carotenoid with a variety of biological activities. This study aimed to demonstrate the possible mechanisms by which AST improves skeletal muscle atrophy in cancer cachexia. In this study, the effects of different doses of AST (30 mg/kg b.w., 60 mg/kg b.w. and 120 mg/kg b.w.) on skeletal muscle functions were explored in mice with cancer cachexia. The results showed that AST (30, 60 and 120 mg/kg b.w.) could effectively protect cachexia mice from body weight and skeletal muscle loss. AST dose-dependently ameliorated the decrease in myofibres cross-sectional area and increased the expression of myosin heavy chain (MHC). AST treatment decreased both the serum and muscle level of IL-6 but not TNF-α in C26 tumor-bearing cachexia mice. Moreover, AST alleviated skeletal muscle atrophy by decreasing the expression of two muscle-specific E3 ligases MAFBx and MuRF-1. AST improved mitochondrial function by downregulating the levels of muscle Fis1, LC3B and Bax, upregulating the levels of muscle Mfn2 and Bcl-2. In conclusion, our study show that AST might be expected to be a nutritional supplement for cancer cachexia patients.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Caquexia
/
Atrofia Muscular
/
Músculo Esquelético
/
Xantofilas
Limite:
Animals
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article